  
 
 
Pilot study, blinded randomized control trial, single center study to compare 
Acetaminophen & Codeine  versus Ibuprofen/Acetaminophen for pain control and 
patient satisfaction after ambulatory hand surgery  
  
 
Principal Investigator  (1) David Steinberg, MD.  
Assistant Professor of Orthopedic Surgery, University of 
Pennsylvania School of Medicine  
Director of  Hand and Microsurgery Fellowship, University of 
Pennsylvania School of Medicine  
Attending Orthopedic Surgeon at Hospital of the University of 
Pennsylvania, Child ren’s Hospital of Philadelphia, Presbyterian 
Medical Center, Pennsylvania Hospital, and Phila delphia  
Veteran’s Affairs Medical Center  
3737 Market Street, 6th floor Orthopedic Department , Philadelphia, 
PA, 19104  
P: 215 -662-3344 ; F: 215 -614-0620 ; 
david.steinberg@uphs.upenn.edu  
 
Investigator  (2) 
 Stephanie  Thibaudeau, MD . CM.  
Orthopedic Surgery , Hand Surgery Fellow  
3737 Market Street, 6th floor Orthopedic Department, Philadelphia, 
PA, 19104  
267-324-7480  
stephanie.thibaudeau@uphs.upenn.edu  
Funding Sponsor :  Penn Presbyterian Medical Center Bach Fund Award  
Sami Khella  
Chair of Bach Fund Committee  
3642 Market St  
Philadelphia, PA 191 04-2682   
Grant Number                                
Penn Presbyterian Medical Center Bach Fund  Award  
 
Protocol Number:  
 
IRB Number:  Penn -Hand 1.0  
823043   
ClinicalTrials.gov Number                   
[STUDY_ID_REMOVED]  
 
    Version              1.7, 03-04-2016  
  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 Table of Contents  
 
Contents  
LIST OF ABBREVIATION S................................ ................................ ................................ ..........................  V 
STUDY SUMMARY  ................................ ................................ ................................ ................................ ...... 1 
BACKGROUND AND STUDY  RATIONALE  ................................ ................................ ................................  4 
INTRODUCTION  ................................ ................................ ................................ ................................ ............  4 
1.1 BACKGROUND AND RELEVANT LITERATURE  ................................ ................................ .....................  4 
2 STUDY OBJECTIVES  ................................ ................................ ................................ .........................  4 
2.1 PRIMAR Y OBJECTIVE : ................................ ................................ ................................ .....................  5 
2.2 SECONDARY OBJECTIVES : ................................ ................................ ................................ ..............  5 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................................ ..................  5 
3.1 GENERAL DESIGN  ................................ ................................ ................................ ..........................  5 
3.1.1  Screening Phase  ................................ ................................ ................................ .....................  6 
3.1.2  Study Intervention Phase  ................................ ................................ ................................ ........  6 
3.1.3  Follow Up Phase  ................................ ................................ ................................ .....................  6 
3.1.4  Allocation to Interventional Group  ................................ ................................ ...........................  7 
3.2 STUDY ENDPOINTS ................................ ................................ ................................ .........................  7 
3.2.1  Primary Study Endpoints  ................................ ................................ ................................ .........  7 
3.2.2  Secondary Study Endpoints  ................................ ................................ ................................ .... 7 
4 STUDY POPULATION AND  DURATION OF PARTICIP ATION  ................................ ........................  7 
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ ......................  7 
4.2 EXCLUSION CRITERIA  ................................ ................................ ................................ .....................  7 
4.3 SUBJECT RECRUITMENT  ................................ ................................ ................................ .................  7 
4.4 DURATION OF STUDY PARTICIPATION  ................................ ................................ ..............................  8 
4.5 TOTAL NUMBER OF SUBJECTS AND SITES................................ ................................ ........................  8 
4.6 VULNERABLE POPULATIONS : NONE  ................................ ................................ ................................ ...... 8 
5 STUDY INTERVENTION ( STUDY DRUG, DEVICE, BIOLOGIC, VACCINE, F OOD ETC.)  ...............  8 
5.1 DESCRIPTION  ................................ ................................ ................................ ................................ . 8 
5.2 INTERVENTION REGIMEN  ................................ ................................ ................................ ................  8 
5.3 SUBJECT COMPLIANCE MONITORING  ................................ ................................ ...............................  9 
5.3.1  Return or Destruction of Investigational Product  ................................ ................................ ..... 9 
6 STUDY PROCEDURES  ................................ ................................ ................................ .......................  9 
6.1 SCREENING  ................................ ................................ ................................ ................................ ... 9 
6.2 STUDY INTERV ENTION PHASE  ................................ ................................ ................................ ....... 10 
6.2.1  Visit 1 (operative day)  ................................ ................................ ................................ ............  10 
6.2.2  Follow Up  ................................ ................................ ................................ ...............................  10 
6.2.3  End of S tudy Visit  ................................ ................................ ................................ ..................  10 
6.3 UNSCHEDULED VISITS ................................ ................................ ................................ ..................  10 
6.4 SUBJECT WITHDRAWAL /EARLY TERMINATION VISITS ................................ ................................ ..... 10 
6.4.1  Data Collection and Follow -up for Withdrawn Subjects  ................................ ........................  10 
6.5 MEDICAL RECORD REVIEW  ................................ ................................ ................................ ...........  10 
6.6 PHYSICAL EXAMINATION  ................................ ................................ ................................ ...............  11 
6.7 VITAL SIGNS: N/A ................................ ................................ ................................ ........................  11 
6.8 LABORATORY EVALUATIONS  ................................ ................................ ................................ .........  11 
6.9 PREGNANCY TESTING  ................................ ................................ ................................ ..................  11 
6.10  OTHER EVALUATIONS , MEASURES  ................................ ................................ ................................  11 
7 STATISTICAL PLAN  ................................ ................................ ................................ .........................  11 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 ALL ANALYSES COMPARI NG THE TREATMENT GRO UPS WERE CONDUCTED O N AN 
INTENTION -TO-TREAT BASIS. TWO -TAILED TESTS WERE US ED AT ALL TIMES, AND  
STATISTICAL SIGNIFIC ANCE WAS SET A PRIOR I AT P<0.05.  ................................ ............................  11 
7.1 PRIMARY ENDPOINT  ................................ ................................ ................................ .....................  11 
THE PRIMARY END POINT  OF THIS STUDY IS PAI N INTENSITY , MEASURED WITH A 100-MM VAS  (WITH 0 MM BEING 
NO PAIN A ND 100 MM BEING MAXIMUM PAI N), AND ANALYZED AS DAIL Y MEAN SCORES .  IN PATIENTS THAT WILL  
HAVE FORGOTTEN TO CO MPLETE THE VAS  SCORES 4 TIMES DAILY , THE MISSING VALUES W ILL BE COMPLETED WIT H 
THE LAST RECORDED SC ORE. ................................ ................................ ................................ .......................  11 
7.2 SECONDARY ENDPOINTS  ................................ ................................ ................................ ..............  11 
7.3 SAMPLE SIZE AND POWER DETERMINATION  ................................ ................................ ...................  11 
7.4 STATISTICAL METHODS  ................................ ................................ ................................ ................  11 
7.4.1  Baseline Data  ................................ ................................ ................................ ........................  11 
7.5 SUBJECT POPULATION (S) FOR ANALYSIS  ................................ ................................ .......................  12 
8 SAFETY AND ADVERSE E VENTS  ................................ ................................ ................................ ... 12 
8.1 DEFINITIONS  ................................ ................................ ................................ ................................  12 
8.1.1 Adverse Event  ................................ ................................ ................................ ...........................  12 
8.1.2  Serious Adverse Event  ................................ ................................ ................................ ..........  12 
8.2 RECORDING OF ADVERSE EVENTS  ................................ ................................ ................................  12 
8.3 RELATIONSHIP OF AE TO STUDY  ................................ ................................ ................................ ... 12 
8.4 REPORTING OF ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ................................ ...............  12 
8.2 UNBLINDING PROCEDURES  ................................ ................................ ................................ ...........  13 
8.3 MEDICAL MONITORING  ................................ ................................ ................................ .................  13 
9 STUDY ADMINISTRATION , DATA HANDLING AND RECORD KEEPING  ................................ .... 13 
9.1 CONFIDENTIALITY  ................................ ................................ ................................ .........................  13 
9.2 DATA COLLECTION AND MANAGEMENT  ................................ ................................ ..........................  13 
THE DEPARTMENT OF ORTHOPAEDICS HAS TWO STANDARD METHODS TO CAPTURE ELECTRONIC D ATA: THESE ARE 
REDCAP AND SECURE DEPART MENTAL SHARED DRIVES  ON THE UPHS  SERVERS  BEHIND THE UPHS  FIREWALLS . 
WE ALSO ROUTINELY COD E FILES BY ASSIGNING  SUBJECT STUDY ID NUMBERS . ................................ ................  13 
DATA WILL ONLY BE ACC ESSED BY INVESTIGATORS IDENTI FIED ON THE IRB.   DATA WILL BE STORED F OR AT LEAST 
7 YEARS AFTER THE STUD Y ENDS . ................................ ................................ ................................ ................  13 
9.3 RECORDS RETENTION  ................................ ................................ ................................ ..................  13 
10 STUDY MONITORING, AU DITING, AND INSPECTI NG ................................ ................................ .. 13 
10.1  AUDITING AND INSPECTING  ................................ ................................ ................................ ...........  13 
11 ETHICAL CONSIDERATIO NS ................................ ................................ ................................ ..........  13 
11.1  RISKS ................................ ................................ ................................ ................................ ..........  14 
11.2  BENEFITS  ................................ ................................ ................................ ................................ .... 14 
11.3  RISK BENEFIT ASSESSMENT  ................................ ................................ ................................ .........  14 
11.4  INFORMED CONSENT PROCESS / HIPAA  AUTHORIZATION  ................................ ..............................  14 
PATIENTS WILL BE ADUL TS CAPABLE OF PROVID ING INFORMED CONSENT  FOR THEMSELVES . PATIENTS WILL BE 
IDENTIFIED FROM ROUT INE CLINICAL ENCOUNT ERS AND WILL BE INVI TED  TO PARTICIPATE IN TH E STUDY BY A 
MEMBER OF THE STUDY TEAM . THE PATIENT WILL BE P ROVIDED THE INFORMED  CONSENT FORM (ICF)  AND THE 
STUDY TEAM MEMBER WI LL DESCRIBE THE STUD Y. THE PATIENT WILL ALSO  BE GIVEN AN OPPORTUN ITY TO READ 
THE ICF  AND TO ASK QUESTIONS  ABOUT THE STUDY . WE WILL LET PATIENTS KNOW THAT THEY ARE A BLE TO 
WITHDRAW FROM THE ST UDY AT ANY TIME . WRITTEN CONSENT WILL BE OBTAINED FROM THE  PATIENT AT THE 
TIME OF CLINICAL ENC OUNTER FOR SURGICAL SCHEDULING . ................................ ................................ ..........  14 
12 STUDY FINANCES  ................................ ................................ ................................ ............................  14 
12.1  FUNDING SOURCE  ................................ ................................ ................................ ........................  14 
12.2  CONFLICT OF INTEREST  ................................ ................................ ................................ ................  14 
12.3  SUBJECT STIPENDS OR PAYMENTS  ................................ ................................ ...............................  14 
13 PUBLICATION PLAN  ................................ ................................ ................................ ........................  14 
14 REFERENCES  ................................ ................................ ................................ ................................ ... 14 
 
 
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
  
 
  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
  
List of Abbreviations  
 
AE: Adverse event  
OTC: Over the counter  
T3: Tylenol -3 
VAS: Visual Analogue Scale  
 
 
 
 
 
 
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 Study Summary  
Title Blinded Randomized Control Tri al 
Optimizing Post-Operative Pain Control in Ambulatory Hand Surgery:  
 Acetaminophen & Codeine  versus Ibuprofen/Acetaminophen  
 
Short Title  Acetaminophen & Codeine  versus Ibuprofen/Acetaminophen in Ambulatory 
Hand Surgery  
 
IRB Number  823043  
Protocol Number  Penn -Hand  1.0 
Phase  Pilot Study  
Methodology  Double blinded randomized control trial  
Study Duration  12 months   
Study Center(s)  University of Pennsylvania Hospital System  
Objectives  Primary:  
To establish, through a randomized control trial, whether post -operative 
Acetaminophen and Ibuprofen (non -opioid regimen) would provide equivalent post -
operative analgesia to ambulatory hand surgery patients compared to Acetaminophen 
and Codeine  (opioid re gimen).  
Primary Outcome variable: VAS pain score  
Secondary:  
To establish whether the opioid versus non -opioid post -operative pain regimen 
influences patient satisfaction.  
Secondary outcome variables: Qua lity of Recovery (QoR) scores; R ate of side effects; 
Rate of medication discontinuation  
Number of Subjects  Sixty -three  patients enrolled for each group  (non-opioid and opioid) . Approximately 
145 patients will be required to achieve complete data for 63 patients in each group  
(assuming 15% lost to follow -up & failure to comply with study protocol) . 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 Main Inclusion and 
Exclusion Criteria  Inclusion criteria : Patients > 18 years old, undergoing ambulatory hand surgery for 
carpal tunnel and trigger finger, under local anesthesia +/ - sedation.  
Exclusion criteria : ASA> 3; coagulopathy; renal disease, liver disease, history of 
recent gastro -intestinal bleeding,  peptic ulcer disease,  congestive heart failure, 
previous stroke, pregnancy. Patients with a diagnosis of chronic pain currently taking 
opioid pain medication or with a history of drug abuse. Patients with a self -described 
allergy to ASA, acetaminophen, NSAIDS and codeine. All patients receiving a 
brachial plexus block for anesthesia and/or analgesia will be excluded.  
 
Investigational 
Product (drug, 
biologic, device , etc. ) 
For Device include 
the planned use  
For Drug , food, 
cosmetic, etc.  
include the dose, 
route of 
administration and 
dose regiment  This is a non -superiority trial to compare two over the counter drug medications 
(OTCs) on post -operative pain contr ol in ambulatory hand surgery:  
Group 1: Acetaminophen 6 50 mg;  Ibuprofen 400 mg  
Group 2: Acetaminophen and codeine  (acetaminophen 300mg, codeine 30 mg)  
Route: oral tablets  
Frequency: Every 6  hours as needed for pain (4 times  daily)  
All of the medications are administered according to  their drug monographs.  
Duration of 
administration  Thirty tablets of  analgesic medication will be provided to the patient  
Reference therapy  In this non -superiority randomized trial, t he medications (acetaminophen, ibuprofen 
and acetaminophen/codeine) and the doses in this randomized control trial are 
currently prescribed by physicians at the University of Pennsylvania Health Services 
Orthopedics Department as standard of care and will be used according to drug 
monographs  and FDA regulations.  
Statistical 
Methodology  All analyses comparing the treatment groups will be conducted on an intention -to-treat 
basis  for patients that will have taken at least one dose. S tatistical significance set a 
priori at P<0.05.   
Safety Evaluations  Potential psychological and physical risks to the study participants are minimal as we 
are not altering standard of care. Acetaminophen, ibuprofen and codeine have well 
described pharmacokinetics and minimal si de effect profile in appropriately selected 
patients (refer to inclusion/exclusion criteria)16.  
If the patient experiences self -described pain that is poorly controlled or an adverse 
event, their physician or treatment team will evaluate the patient as deemed 
appropriated and prescribe alternative medications i f necessary.  
Contact information will be provided to all study participants to ask questions at any 
time during the study.  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 Data and Safety 
Monitoring Plan  Data will be collected using the Research Electronic Database Capture (RedCap) , a de -
identified  database.  
 
  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 BACKGROUND AND STUDY  RATIONALE  
This study will be conducted in full accordance all applicable University of Pennsylvania Research Policies and 
Procedures and all applicable Federal and state laws and regulations . 
Introduction  
1.1 Background and Relevant Literature  
 
Prescription drug overdose has become a serious public health issue and with exploding associated health care costs7 8. This 
opioid epidemic is not an isolated problem as underlined by a 2013 report by Trust for America’s Health in which Philadelphia  
was ranked as 14th nationwide for dr ug overdose related deaths.  
Ninety -nine percent of carpal tunnel surgery and other hand soft tissue releases such as trigger finger, are performed in the 
ambulatory setting 9,10. Post -operative pain prescriptions vary widely across hand surgeons in North America. In one study, 
Canadian hand surgeons prescribed opioids to 5 % of their ambulatory hand surgery patients whereas physicians in the United 
States prescribed opioids for 66% of their patients for similar surgeries11. Studies have investigated the role of post -operative 
non-steroidal anti -inflammatory (NSAIDS) in post -operative pain control for outpatient general surgery2,3. Given that there is no 
gold standard regimen for post -operative pain control after ambulatory hand surgery and considering the current opioid epidemic 
in the United States, it would be of utmost importance to establish whether a non -opioid pain regimen would provide equivalent 
post-operative analgesia to han d surgery patients. Our long term goal is to decrease opioid drug diversion while maintaining 
adequate pain relief and patient satisfaction.  
Patient satisfaction has become an increasingly important metric in healthcare quality and importantly in healthcar e payment 
policies12. In fact the Centers for Medicare & Medicaid Services (CMS) incorporated patient satisfact ion in part of their value 
based incentive payments since 201213. Quality of Recovery has been linked to patient satisfaction after anesthesia and surgery6. 
Determining if the post -operati ve pain regimen has an influence on the Quality of Recovery Score is of prime importance in the 
consumer model of health care.  
 
2 Study Objectives  
 
The purpose of our study is to conduct a randomized control trial to determine whether a non -opioid based pai n regimen is 
equivalent to an opioid analgesic to control post -operative pain after ambulatory hand surgery ( Aim 1 ). At the UPHS 
Orthopedics Department, approximately 600 cases of carpal tunnel and trigger finger releases are performed yearly. These 
patien ts commonly receive a Tylenol 3 script (acetaminophen 300mg, codeine 30 mg). If the script is placed electronically, the 
system automatically reverts it to the generic equivalent.  If the patient self -describes a previous adverse events to Tylenol 3 
(T3), the script is commonly substituted for oxycodone -acetaminophen (5mg -325mg). Drug diversion and the opioid epidemic in 
the United States is a public health concern and surgeons have the obligation to responsibly prescribe opioids for post -operative 
analgesi a. Our ambulatory hand surgery patient population represents a unique opportunity for hand surgeons at UPHS to 
optimize post -operative pain prescription habits and study its impact on patient satisfaction. Our long term goal is to optimize 
post-operative p rescription practices at our institution and in hand surgery nationwide, while maintaining patient satisfaction 
(Aim 2)  and ultimately decrease drug diversion potential.  
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 2.1 Primary Objective : 
 
To establish, through a randomized control trial, whether post -operative Acetaminophen  and Ibuprofen (non -opioid regimen) 
would provide equivalent post -operative analgesia to ambulatory hand surgery patients compared to Acetaminophen and 
Codeine  (opioid regimen).  
Rationale:  In the setting of ambulatory hand surgery, many of the opioid pain scripts are not utilized. In a telephone survey of 
patients undergoing ambulatory hand surgery, 52% of patients reported taking their prescribed analgesics for 2 days o r less1. 
Ninety -nine percent of these patients received a 30 -tablet script for narcotics, leaving the left -over narcotics available for 
diversion. Studies have investigated the role of post -operative non -steroidal anti -inflammatory (NSAIDS) in post -operative pain 
control for outpatient surgery23,4, though never as a randomized control trial in hand surgery.  
Hypothesis:  A non -opioid post -operative regimen of ibuprofen and acetaminophen is equally effective with less side effects as 
Acetaminophen and codeine  for pain relief in the context of ambulatory hand surgery.  
Primary Outcome Variable:  Visual Analogue Scale Pain Score  
2.2 Secondary Objectives : 
 
To establish whether the opioid versus non -opioid post -operative pain regimen influences patient satisfaction through Quality of 
Recovery (QoR) scores in ambula tory hand surgery.  
Rational:  Quality of Recovery score is a validated health measure based on the answers of a 9 -item questionnaire administered to 
patients after anesthesia5. The Quality of Recovery score has been shown to correlate with patient satisfaction post-operatively6.  
Hypothesis:  A non -opioid post -operative regimen will have equivalent Quality of Recovery scores to an opioid post -operative 
pain regimen.  
Secondary Outcome Variables : Adverse events, duration of medication intake, reason for medication discontinuat ion, patient 
satisfaction as determined by the Quality of Recovery -9 (QoR -9). 
3 Investigational Plan  
3.1 General Design  
 
Small scale, pilot, blinded randomized non -superiority control trial  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
  
 
 
 
 
3.1.1  Screening Phase  
Patients will be screened  through the clinical practices of Penn Orthopaedics. Scheduled clinic encounters are documented in EPIC. 
Chief complaint or reason for visit is typically captured which will be the primary source of identifying possible patients. Once it is 
determined eit her through EPIC or in the course of the clinical encounter that a patient is presenting with carpal tunnel syndrome or 
trigger fingers they will be evaluated for eligibility by for this study by the study team.  
3.1.2  Study Intervention Phase  
Patients who meet the inclusion  criteria will be randomized into one of two post -operative analgesia treatment groups: an opioid 
treatment group versus anti -inflammatory and acetaminophen (400mg/650mg) treatment group. Patients in one group will receive 
either 650  mg of ace taminophen and 400  mg of ibuprofen per dose. Patients in group two will receive  300mg of acetaminophen and 
30 mg of codeine (T3 equivalent) per dose. The active medications will be encapsulated into identical capsules containing half o f the 
full dose (2 ca psules  = 1 dose). The capsules will then be dispensed in identical bottles . The first dose will be administered in the post -
anesthesia care unit (PACU).  The visual analogue scale (VAS) is simple and commonly used in the clinical setting to measure pain 
severity14,15. The patients will complete a post -operative pain diary. The entries will consist of a VAS, time of medication intake 
and side effects (nausea, vomiting, constipation, dizziness, other). Date and reasons for medication discontinuation (pain fr ee 
versus adverse effect) will also be recorded. The first entry will be recorded pre-operatively to ensure comprehension of the 
VAS as well as to obtain baseline pain score. The second entry will be in the recovery room.  The patients will complete four 
entries daily which corresponds to allowed intake of pain medication over a period o f 5 days. Patient will return the diary on the first 
post-operative visit (ranging from 6 to 8 days post -operatively). All patients will be called on post -operative day 2 in order to complete 
the Quality of Recovery Questionnaire. The 9 -item questionnaire will be administered via a telephone interview by a clinical assistant 
who is blinded to the treatment arm.  
  
3.1.3  Follow Up Phase  
 Outpatient 
Clinic 
Appointmen
t 
Patient 
booked for 
carpal tunnel 
or trigger 
finger release  Patient meets 
inclusion 
criteria  Introduced to 
protocol  
Consent 
signed  Surgery  
Patient 
Randomized  
to 
 Treatment 
Group  Post -op d2:   
Telephone 
reminder:  
pain diary; 
QOR -9 Post -op d6:   
Telephone 
reminder: 
bring pain 
diary to clinic  Post -op d7:  
1st post -
operative 
follow -up 
Data entry 
completed  
Post -op day 0  to day 6 
Patient completes pain diary 4x daily  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 Patients will return to hand clinic per their usual post -operative visit  schedule. Their first visit generally rang es from 6 to 8 days  after 
their surgery . At this visit the patient will return the diary  and remaining medication . This will conclude the patient’s participation in 
the study.  
3.1.4  Allocation to Interventional Group  
Stratified block randomization using tables o f random numbers, stratified according to hand surgery type (carpal tunnel, trigger finger) 
will be used to ensure equivalent numbers of patients in each treatment group for each of the 2 procedures. Patients wi ll be 
randomized in blocks of 4 . Randomization will be performed by the Investigational Drug Service (IDS) using computer -generated 
tables.  The treatment allocation will be concealed from the study investigators, physicians, nurses, patients, and statistic ian. 
Allocation assignments wi ll be held securely in the IDS until all primary analyses are performed; this code will be broken for 
subgroup and post hoc analyses. Patients who meet the inclusion criteria will be randomized into one of two post -operative analgesia 
treatment groups: an opioid treatment group versus anti -inflammatory and acetaminophen (400mg/650mg) treatment group. Patients 
in one group will receive either 650  mg of acetaminophen and 400  mg of ibuprofen per dose. Patients in group two will receive 300mg 
of acetaminophen a nd 30  mg of codeine (T3 equivalent) per dose. The active medications will be encapsulated into identical capsules 
containing half of the full dose (2 capsules  = 1 dose). The capsules will then be dispensed in identical bottles. In this manner, both 
patient s and investigators are blinded.  
3.2 Study Endpoints  
3.2.1  Primary Study Endpoints  
Ten millimeter Pain Visual Analogue Scale.  
 
We chose a threshold of 5  mm difference in VAS score to ensure that even a smaller efficacy difference could be identified 
statistically . 
 
3.2.2  Secondary Study Endpoints  
Adverse events, duration of medication intake, reason for medication discontinuation, patient satisfaction as determined by t he Quality 
of Recovery -9 (QoR -9). 
4 Study Population and Duration of Participation  
4.1 Inclusion Criteria  
Patients > 18 years old, undergoing ambulatory hand surgery for carpal tunnel  and trigger finger, under local anesthesia with or 
without  sedation.  
4.2 Exclusion Criteria  
ASA> 3; coagulopathy; renal disease, liver disease, history of recent gastro -intestinal bleeding, pregnancy. Patients with a diagnosis of 
chronic pain currently taking opioid pain medication or with a history of drug abuse. Patients with a self -described allergy to ASA, 
acetaminophen, NSAIDS and codeine. Finally all patients receiving a brach ial plexus block for anesthesia and/or analgesia will be 
excluded.   
4.3 Subject Recruitment  
Subjects  will be recruited from the investigator s clinical practices . If the patient meet the inclusion criteria, they will be approach by 
the physicians . Should they show interest in the study, a member of the clinical research team will review the study, consent and 
answer any additional questions regarding the protocol.  
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 4.4 Duration of Study Participation  
Enrollment Timeline:  With an average of 10 operations for trigger  finger or carpal tunnel per week, we estimate that with a voluntary 
participation rate of 50%, the enrollment of patients should be complete within 8 months.   
 
Subject Participation:  Individual subjects will participate in the study from the day of their surgery to their first post -operative visit 
(generally 6 to 8 days after their surgery).  
4.5 Total Number of Subjects and Sites  
 
Site: Penn Presbytarian Medical Center  
 
Sample size : 63 per grou p. Assuming a 15% lost to follow -up and failure to comply with study protocol, 1 45 patients will be required 
to achieve complete data for 63 patients in each group.   
4.6 Vulnerable Populations: none 
5 Study Intervention  
 
Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg  
Group 2: Acetaminophen 300mg , Codeine 30 mg  
5.1 Description  
 
Acetaminophen  
 
Please refer to full monograph:  Acet aminophen Entire Monograph - Epocrates Online. 
https://on line.epocrates.com/u/10a307/acetaminophen . 2015. Accessed 6/28/2015  
 
Ibuprofen  
 
Please refer to full monograph: Ibuprofen Entire Monograph - Epocrates Online. https://online.epocrates.com/u/10a234/ibuprofen . 
2015. Accessed 6/28/2015  
 
Acetaminophen and Codeine Phosphate Tablets : combine d analgesic effect  of a centrally acting analgesic, codeine, with a peripherally 
acting analgesic, acetaminophen.  
 
Please refer to the following FDA reference:  
 
Food and Drug Administration. http://www.accessdata.fda.gov/spl/data/f1762dc1 -b238 -47bb -b5ab-33c0156724c5/f1762dc1 -b238 -
47bb -b5ab -33c0156724c5.xml . 5/2011. Accessed 6/28/2015.  
5.2 Intervention Regimen  
 
Dose: Acetaminophen 650 mg; Ibuprofen 400 mg; Codeine 30 mg  
Route: blinded opaque oral capsules  
Frequency: 1st dose given in PACU on day of surgery; every  6 hours as needed for pain (4 times daily)  
Duration: Total of 30 capsules will be distributed to the subjects  
 
5.3 Receipt  
For each subject, IDS would prepare 30 blinded capsules (containing either APAP 300/Co deine 30, or APAP 325/IBU 200 per 
capsule) and dispense from IDS main location (Ground Maloney, HUP) the day before surgery or the IDS satellite (1 Mutch, Penn 
Presbytarian Medical Center) on day before or the morning of surgery.  
 
The IDS will purchase APA P 300mg/Codeine 30mg tablets, APAP 325mg tablets and Ibuprofen 200mg tablets commercially.  IDS 
will purchase pharmaceutical -grade opaque gelatin capsules and NF (National Formulary) grade inert fillers (microcrystalline 
cellulose NF) from FDA -registered f acilities.  All encapsulation takes place using 316 -grade surgical stainless steel equipment.  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
  
5.4 Storage  
All medication will be stored in the Investigational Drug Service, which maintains high level security and is inaccessible to  non-IDS 
personnel, inc luding other members of the study team.  Medication is maintained at USP controlled room temperature (20 -25 Celsius) 
in tightly -sealed containers which comply with USP<671> and the Poison Prevention Packaging Act.  
  
5.5 Preparation and Packaging  
 
Encapsula tion will take place in a controlled environment following cGCP and USP<795> guidelines, with all activities performed by 
trained research technicians and research pharmacists.  
 
Medication will be packaged in standard USP<671> -compliant prescription packag ing by IDS personnel, pursuant to an individual 
signed or electronically -transmitted legal prescription for each study participant.  Medication will be dispensed in a sealed, labeled 
package on the day of surgery and transferred to a member of the study te am who will provide the medication to the participant prior 
to discharge from the surgery center.   
 
5.6 Blinding  
 
The Investigational Drug Service will prepare medication for both treatment conditions, which is indistinguishable to the stu dy team 
or to study participants.  IDS staff will assign subjects sequentially to treatment arms following the secure randomization tables 
(maintained in the IDS) as prescriptions are received and medication dispensed.  
 
The IDS maintains an emergency unmasking website t hrough Penn Medicine Academic Computing Services, through which the PI 
can, in an emergency situation, obtain access to the treatment assignment for one individual p articipant.  The website is secured both 
through PennKey authentication and because only an  IDS pharmacist can grant individual user access to an individual trial.  The 
website maintains an audit trail of all unmasking activity and categorizes requests for later follow -up.   
 
 
5.7 Administration and Accountability    
 
The IDS accounts for all study medications, including bulk purchased medications as well as blinded capsules, through an electronic 
accountability record system in compliance with 21CFR11.  The record system is accessible only to IDS personnel and the Direc tor of 
IDS has ultimate control over all user accounts.  The system uses electronic, time/date -stamped signatures for every transaction, as 
well as maintains patient profiles which span all research participation longitudinally as well as across all schools and res earchers who 
use IDS services, in compliance with Pennsylvania Code.  
 
5.3 Subject Compliance Monitoring  
Patients enrolled in the study are asked to complete a post-operative pain diary  (please refer to attached) .  
In this diary, they are asked to record side effects and the number of doses taken within a 24 hour  period .  
The patients will be asked to return the remaining tablets. This number of remaining tablets should match their diary entries .  
5.3.1  Return or Destruction of Investigational Product  
 
The patients will be asked to return the remaining number of tablets on their first post -operative visit.  
 
Any unused medication at the end of a subject’s course of treatment, is returned to the IDS, where research technicians count  and log 
the returned quantities under the subject’s profile in the accountability system.  Electronic, blinded patient -return reports can be 
generated for the study team to assist in calculating patient compliance with the regimen.  
6 Study Procedures  
6.1 Screening  
The screening visit will take place during the patient’s  clinical encounter to schedule an operation for trigger finger or carpal tunnel.  
 Informed Consent  
 Medical Record Review  to determine eligibility  
 Physical Exam  (Height and Weight)   
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 6.2 Study Intervention Phase  
6.2.1  Visit 1 ( operative day)   
Patients will be  randomized to either study group the day of their su rgery .  They will receive the first dose of the study medication 
while they are in the recovery room.  Subjects will complete the pain diary 4 times every day following surgery (3 times the day of 
surger y).   
6.2.2  Follow Up   
 
Telephone:  Patients will be contacted by telephone on their 2nd post-operative day to administer the QoRs -9. Patients will also be 
telephoned on the day prior to their first post -operative visit as a reminder to bring the diary and remain der of the medication.  
Clinic Visit: Patients will return to clinic for their first post -operative visit (generally 6 to 8 days after their surgery).  
 
6.2.3  End of Study Visit  
 
The study will conclude at the time of the patient’s first post -operative encounter  with their treating hand surgeon (usually between 6 
to 8 post -operative days) . After conclusion of the study, the patient’s will continue on their regular post -operative schedule as deemed 
necessary by the treating hand surgeon.  
 
Patients will be unblinde d after final data analysis.  
6.3 Unscheduled Visits  
All patients will be able to contact their treating physician during the course of the study , and/or schedule an early visit if deemed 
necessary . Data collection will proceed as initially described unless the  patient requires unblinding.  
6.4 Subject Withdrawal /Early Termination Visits   
If the patient experiences self -described pain that is poorly controlled or an adverse event, their physician or treatment team will 
evaluate the patient as deemed appropriated and prescribe alternative medications  if necessary.  Subjects who withdraw early will 
continue to follow with their treating hand surgeons as per standard of care.  We will follow intention to treat in our statistical analysis. 
Hence if a patient requires unblin ding, the last available measurement for each individual at the time point prior to withdrawal from 
the study will be retained in the analysis . 
6.4.1  Data Collection and Follow -up for Withdrawn Subjects  
Data collection will stop for withdrawn subjects .  If patie nts fail to follow -up, they will be contacted by telephone. If they were 
compliant with the diary completion, we will ask the patient to mail the diary or to bring the diary at their next scheduled appointment. 
We will follow ITT in our statistical analysi s, thereby  the last available measurement for each individual at the time point prior  to 
withdrawal from the study will be  retained in the analysis . 
 
6.5 Medical Record Review  
 Date of birth  
 Height  
 Weight  
 Past medical history with particular focus on:  
 coagulopathy  
 renal disease   
 liver disease  
 thromboembolic disease (stroke)  
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
  history of recent gastro -intestinal bleeding  or peptic ulcer disease  
  pregnancy  
 chronic pain currently taking opioid pain medication or with a history of drug abuse  
 self-described al lergy to ASA, ac etaminophen, NSAIDS and codeine   
6.6 Physical Examination  
 Height  
 
 Weight  
6.7 Vital Signs : N/A  
6.8 Laboratory Evaluations  
 
Standard pre -operative work -up as indicated for the patient’s past medical history and surgical risk factors.  
6.9 Pregnancy Testing  
A urine pregnancy test will done the day of the surgery for all women of child -bearing age per usual pre -operative work -up. Patients 
with a positive urine pregnancy test will be excluded from the study.  
6.10 Other Evaluations, Measures  
Visual Analogue Scale, di ary and QoR -9 (please refer to attached)  
 
7 Statistical Plan  
All analyses comparing the treatment groups were conducted on an intention -to-treat basis. Two -tailed tests were used at all times, and 
statistical significance was set a priori at P<0.05.  
7.1 Primary  Endpoint  
The primary end point of this study is pain intensity,  measured with a 100 -mm VAS (with 0 mm being no pain and 100 mm being 
maximum pain), and analyzed as daily mean scores.  In patients that will have forgotten to complete the VAS scores 4 times  daily, the 
missing values will be completed with the last recorded score.  
7.2 Secondary Endpoints  
Adverse events, duration of medication intake, reason for medication discontinuation, patient satisfaction as determined by t he Quality 
of Recovery -9 (QoR -9). 
7.3 Sample Size and Power Determination  
A sample size of 63 in each group has 80  % power to detect a difference in means of 5  mm assuming a common standard deviation of 
10 mm by a two -group Student’s t test with a 0.05 two -sided significance level.  Assuming a 3 0% lost to follow -up and failure to 
comply with study protocol, 145 patients will be required to achieve complete data for 63 patients in each group.  
7.4 Statistical Methods  
7.4.1  Baseline Data  
We will use means and standard deviations (SDs), medians and interquartile ranges (IQRs) or frequencies and percentages, as 
appropriate, to summarize baseline characteristics. We will assessed comparisons between participants who did and did not tak e 
analg esia using an unpaired t test for continuous variables and a Pearson χ2 test for categorical variables.  We will use a parametric 
student t test to assess the primary end point (VAS).  
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 7.5 Subject Population(s) for Analysis  
All-treated population :  Any subject s randomized into the study that received at least one dose  of either Acetaminophen/codeine or 
acetaminophen/ibuprofen.  
8 Safety and Adverse Events  
8.1 Definitions  
8.1.1 Adverse Event  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity during the course of the 
study.  Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic procedures a re 
considered to be  adverse events if the abnormality:  
 results in study withdrawal  
 is associated with a serious adverse event  
 is associated with clinical signs or symptoms  
 leads to additional treatment or to further diagnostic tests  
 is considered by the investigator to be of  clinical significance  
 
8.1.2  Serious Adverse Event  
Serious Adverse Event  
Adverse events are classified as serious or non -serious.  A serious adverse event  is any AE that is:  
 fatal 
 life-threatening  
 requires or prolongs hospital stay  
 results in persistent or sig nificant disability or incapacity  
 a congenital anomaly or birth defect  
 an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significan ce.   They 
may jeopardize the su bject, and may require intervention to prevent one of the other serious outcomes noted above.  For example, drug 
overdose or abuse, a seizure that did not result in in -patient hospitalization, or intensive treatment of bronchospasm in an emergency 
departme nt would typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious adverse events .  
 
8.2 Recording of Adverse Events  
 
At each contact with the subject (such as the post -op telephone  calls and the post -op clinic visit), the investigator will seek information 
on adverse events by specific questioning and, as appropriate, by examination.  Information on all adverse events will be rec orded 
immediately in the source document, and also in the appropriate adverse event module of the case report form (CRF).  All clearly 
related signs, symptoms, should be recorded in the source document, though should be grouped under one diagnosis.  
 
All adverse events occurring during the study period will be  recorded.  The clinical course of each event will be followed until 
resolution, stabilization, or until it has been determined that the study intervention or participation is not the cause.  Se rious adverse 
events that are still ongoing at the end of the study period will be followed up to determine the final outcome.  Any serious adverse 
event that occurs after the study period and is considered to be possibly related to the study intervention or study particip ation will be 
recorded and reported immediate ly. 
8.3 Relationship of AE to Study  
The principal investigator will determination the relationship of the AE to the study and will be classified as definitely re lated, 
probably related, possibly related, unlikely or unrelated.  
8.4 Reporting of Adverse  Events and Unanticipated Problems  
We will report adverse events and/or unanticipated problems in accordance with the Penn IRB policy on Reportable Events .   
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
  
8.2 Unblinding Procedures  
The IDS maintains an emergency unmasking website through Penn Medicine Academic Computi ng Services, through which the 
PI can, in an emergency situation, obtain access to the treatment assignment for one individual participant.  The website is 
secured both through PennKey authentication and because only an IDS pharmacist can grant individual user access to an 
individual trial.  The website maintains an audit trail of all unmasking activity and categorizes requests for later follow -up.   
8.3 Medical Monitoring  
The Principal Investigator will oversee the safety of the study.  This safety monitoring will include careful assessment and 
appropriate reporting of adverse events as noted above.  
 
9 Study Administration, Data Handling and Record Keeping  
9.1 Confidentiality  
Information about study subjects will be kept confidential and managed according to the req uirements of the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the s ubject 
of the following:  
 What protected health information (PHI) will be collected from subjects  in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or  use PHI, the investigator, by regulation, retains the ability to use all 
information collected prior to the revocation of subject authorization.  For subjects that have revoked authorization to coll ect or use 
PHI, attempts should be made to obtain permiss ion to collect at least vital status (i.e. that the subject is alive) at the end of their 
scheduled study period.  
9.2 Data Collection and Management  
The Department of Orthopaedics has two standard methods to capture electronic data: these are RedCap  and secure departmental 
shared drives on the UPHS servers behind the UPHS firewalls. We also routinely code files by assigning subject study ID numbe rs.  
Data will only be accessed by investigators identified on the IRB.   Data will be stored for at least 7 years after the study ends.   
9.3 Records Retention  
Study records will be stored for at least 7 years after the study ends.  The storage of the study records will be in accordan ce with 
departmental and institutional policies/requirements.   
10 Study Monitoring , Auditing, and Inspecting  
10.1 Auditing and Inspecting  
The investigator will permit study -related monitoring, audits, and inspections by the EC/IRB, the sponsor, government regulatory 
bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory 
documents, data collection instruments, study data etc.).  The investigator will ensure the capability for inspections of app licable 
study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by government regulatory authoritie s and 
applicable University compliance and quality assurance offices.  
11 Ethical Considerations  
This study is to be conducted in accordance with applicable US government regulations and international standards of Good Clinical 
Practice, and applicable institutional research policies and procedures.  
 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 This protocol and any amendments will be submitted to a properly constituted independen t Ethics Committee (EC) or Institutional 
Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the study conduct.  The decision of t he 
EC/IRB concerning the conduct of the study will be made in writing to the investigator and a copy of this decision will be provided to 
the sponsor before commencement of this study.  
11.1 Risks  
Potential psychological and physical risks to the study participants are minimal as we are not altering standard of care . Risks to subject 
confidentiality  are minimized by the use of vigilant de -identification processes, secure data storage, and private facilities as applicable. 
The patients can choose to opt out of the study at any point in time with no impact on their surgical or medical care.  
11.2 Benefits  
This randomized control study will enable us to determine if pain after ambulatory hand surgery can be adequately controlled with 
non-opioid pain medication as effectively as with opioid pain medication. Results of this study will be submitted to a peer re viewed 
journal such that the results can benefit the medical and general population.  
11.3 Risk Benefit Assessment  
The risks of participating in the study are outweighed by the potential benefits of participating in the study.  
11.4 Informed Consent Process / HIPAA Authorization  
Patients will be adults capable of providing informed consent for themselves. Patients will be identified from routine clinic al 
encounters and will be invited to participate in the study by a member of the study team. The patient will be pro vided the informed 
consent form (ICF) and the study team member will describe the study. The patient will also be given an opportunity to read t he ICF 
and to ask questions about the study. We will let patients know that they are able to withdraw from the s tudy at any  time. Written 
consent will be obtained from the patient at the time of clinical encounter for surgical scheduling.  
12 Study Finances  
12.1 Funding Source  
This study is financed through a grant from the Presbytarian Hospital Bach Fund  in the amount of $11,000  
12.2 Conflict of Interest  
All University of Pennsylvania Investigators will follow the University of Pennsylvania Policy on Confl icts of Interest Related to 
Research .  
12.3 Subject Stipends or Payments  
There are no subject payments or stipends.  
 
Patients will receive the medication (either  Acetaminophen and codeine or Acetaminophen -ibuprofen) free of charge during their 
participation in  the study.   
13 Publication Plan  
This is a single site study. The investigators of this study will submit the results for publication in a peer -reviewed scientific journal.  
 
14 References  
1.  Rodgers J, Cunningham K,  Fitzgerald K, Finnerty E. Opioid consumption following outpatient upper extremity 
surgery. J Hand Surg Am . 2012;37(4):645 -650. doi:10.1016/j.jhsa.2012.01.035.  
2.  Mitchell A, McCrea P, Inglis K, Porter G. A randomized, controlled trial comparing acetamino phen plus ibuprofen 
versus acetaminophen plus codeine plus caffeine (Tylenol 3) after outpatient breast surgery. Ann Surg Oncol . 
2012;19(12):3792 -3800. doi:10.1245/s10434 -012-2447 -7. 
CONFIDENTIAL  
 
This material is the property of the University of Pennsylvania.   
 3.  Raeder JC, Steine S, Vatsgar TT. Oral ibuprofen versus paracetamol pl us codeine for analgesia after ambulatory 
surgery. Anesth Analg . 2001;92(6):1470 -1472. http://www.ncbi.nlm.nih.gov/pubmed/11375827. Accessed May 1, 
2015.  
4.  Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsterodial antiinflamm atory drugs. 
Anesth Analg . 1994;79(6):1178 -1190. http://www.ncbi.nlm.nih.gov/pubmed/7978444. Accessed March 25, 2015.  
5.  PS M, JO H, CE N, Al. E. Development and Psychometric Testing of Quality of Recovery Score After General 
Anesthesia in Adults. Anesth Anal . 1999;88:83 -90. 
6.  Myles P, MDS R, H A, AM W. Measurement of Quality of Recovery in 5672 Patients after Anesthesia and 
Surgery. Anesth Intensive Care . 2000;28:276 -280. 
7.  Manchikanti L, 2nd HS, B F, Al. E. Opioid Epidemic in the United States. Health Policy Review. Pain Physician . 
2012;15:ES9 -ES38.  
8.  King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid -related mortality in the 
United State s and Canada, 1990 -2013: a systematic review. Am J Public Health . 2014;104(8):e32 -e42. 
doi:10.2105/AJPH.2014.301966.  
9.  Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I. Prevalence of carpal tunnel syndrome in a 
general population. JAMA . 1999;282(2):153 -158. http://www.ncbi.nlm.nih.gov/pubmed/10411196. Accessed May 
1, 2015.  
10.  Fajardo M, Kim SH, Szabo RM. Incidence of carpal tunnel release: trends and implications within the United 
States ambulatory care setting. J Hand Surg Am . 2012;37 (8):1599 -1605. doi:10.1016/j.jhsa.2012.04.035.  
11.  Davison PG, Cobb T, Lalonde DH. The patient’s perspective on carpal tunnel surgery related to the type of 
anesthesia: a prospective cohort study. Hand (N Y) . 2013;8(1):47 -53. doi:10.1007/s11552 -012-9474 -5. 
12.  Heather L, Wick EC, Housman M, Freischlag JA, A MM. Patient Satisfaction as a Possible Indicator of Quality 
Surgical Care. JAMA . 2013;148(4):362 -367. 
13.  Services D of H and H. Hospital Inpatient Value -Based Purchasing Program [Centers for Medicare  & Medicaid 
Services web site]. Regist Fed . 2011:26490 -26547. http://www.gpo.gov/fdsys/pkg/FR -2011 -05-06/pdf/2011 -
10568.pdf. Accessed May 1, 2015.  
14.  Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), 
Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short -Form McGill Pain 
Questionnaire (SF -MPQ), Chronic Pain Grade Scale ( CPGS), Short Form -36 Bodily Pain Scale (SF. Arthritis Care 
Res (Hoboken) . 2011;63 Suppl 1:S240 -S252. doi:10.1002/acr.20543.  
15.  Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg 
Med. 1996;27(4):485 -489. http://www.ncbi.nlm.nih.gov/pubmed/8604867. Accessed April 27, 2015.  
16.  Brune K, Patrignani P. New insights into the use of currently available non -steroidal anti -inflammatory drugs. J 
Pain Res . 2015;8:105 -118. doi:10.2147/JPR.S75160.  
  